UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Development of a CD30-directed CAR-T cell for the treatment of relapsed/refractory classical Hodgkin Lymphoma

Fiaccadori, Valeria; (2022) Development of a CD30-directed CAR-T cell for the treatment of relapsed/refractory classical Hodgkin Lymphoma. Doctoral thesis (Ph.D), UCL (University College London).

[thumbnail of PhD_Thesis_Valeria_Fiaccadori.pdf] Text
PhD_Thesis_Valeria_Fiaccadori.pdf - Accepted Version
Access restricted to UCL open access staff until 1 September 2024.

Download (5MB)

Abstract

Relapsed/refractory classical Hodgkin Lymphoma (cHL) represents an unmet clinical need. CD30 is an ideal target for CAR-T cell therapy in cHL, as its expression is high on tumour cells, but limited on healthy tissues. A proportion of activated T cells upregulates CD30, but the extent, duration and consequences of this on CD30-CAR T cell therapy have not been elucidated. Responses in early phase trials employing CD30-CAR T cells are encouraging, but their duration needs to be improved. To develop an efficacious CD30-CAR T cell, first I studied 11 CD30-binders for binding kinetics, stability and epitope binding. I tested them in vitro as second generation, 41BB co-stimulated CARs for cytotoxicity, cytokine release and proliferation against CD30+ targets. Binder 2 was selected for the best combination of on-target cytotoxicity and IL2 secretion. I studied CD30 expression on T cells at several timepoints after single activation. Expression peaked between day +4 and +5. By day +11, <10% of non-transduced T-cells expressed CD30, compared to up to 50% of CD30-CARs. These cells showed higher expression of activation markers (CD69 and CD62L). To elucidate its impact on CD30-CAR T cells activity, I knocked out CD30 on T cells using CRISPR-Cas9. I tested different timelines to incorporate editing in my in vitro CARs manufacturing and showed that editing non activated T cells was feasible, effective and did not impair subsequent activation or transduction. When tested in vitro, though, CD30 KO CD30-CARs did not show a statistically significant advantage compared to their non-edited counterpart and they achieved inferior tumour control In vivo, in an immunocompromised model. This works generated an efficacious second generation CD30-CAR, which will be used as backbone for further engineering and translation into clinic. While CD30 expression is high and persistent in CD30-CAR T cells, it does not appear to impact significantly on their activity in vitro and in vivo.

Type: Thesis (Doctoral)
Qualification: Ph.D
Title: Development of a CD30-directed CAR-T cell for the treatment of relapsed/refractory classical Hodgkin Lymphoma
Language: English
Additional information: Copyright © The Author 2022. Original content in this thesis is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) Licence (https://creativecommons.org/licenses/by-nc/4.0/). Any third-party copyright material present remains the property of its respective owner(s) and is licensed under its existing terms. Access may initially be restricted at the author’s request.
UCL classification: UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL
URI: https://discovery.ucl.ac.uk/id/eprint/10153746
Downloads since deposit
3Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item